PCA3 is a clinically approved biomarker with high sensitivity and specificity for the detection of early prostate cancer from urine samples, while the MALAT1 assay is more useful in patients with borderline prostate-specific antigen (PSA) levels. Here, KLK3 is linked to prostate carcinoma.